MeMed’s Presentation Theater at 

MeMed is transforming patient care by listening to the immune system and turning host response signals into clinical action.

Watch theater presentation

Is it a bacterial or viral infection? Using host-response technologies to decode the immune system and aid antibiotic stewardship

What would your practice look like if you had a 15-minute test that could differentiate between a bacterial and viral infection? MeMed BV® is the first rapid and accurate (blinded and external validation) host-response technology for distinguishing between bacterial and viral infections in under 15 minutes, and it is changing the paradigm in infectious disease patient management.

About MeMed

At MeMed, a leader in host response technologies, we decode the body's complex signals into simple insights that improve people's lives. By leveraging our expertise in host-response profiling and machine-learning algorithms, we are creating a portfolio of tests that address tough clinical dilemmas.

Importantly, with the support of public and private partnerships, we have developed a point-of-need, rapid measurement platform called MeMed Key® to ensure timely availability of these novel tests during the clinician’s decision-making workflow.

Contact us

Come join MeMed's Presentation Theater at IDWeek 

Sheldon L. Kaplan, MD

Head, Pediatric Infectious Disease Section, Baylor College of Medicine

New Developments in Infectious Diseases Diagnostics:

112 - A Rapid Host-Protein Signature Based on TNF-related Apoptosis-Induced Ligand (TRAIL), Interferon Gamma Induced Protein-10 (IP-10) and C-Reactive Protein (CRP) Accurately Differentiates Between Bacterial and Viral Infection in Febrile Children: Apollo Sub-Study.

Alon Angel

International Investigator Award Product Associate, MeMed

COVID-19 Complications, Co-infections and Clinical Outcomes: 

32 - Host Immune-Protein Signature Combining TRAIL, IP-10 and CRP for Early and Accurate Prediction of Severe COVID-19 Outcome